Showing results (331-340 of 390) with videos related to
Sort By:
Pageof 39
Cancer Research|May 11, 2017
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung CancerSai Kiran Sharma, Jacob Pourat, Dalya Abdel-Atti, et al.Journal of Consulting and Clinical Psychology|July 29, 2009
Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disordersDenise A Hien, Elizabeth A Wells, Huiping Jiang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2020
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate CancerAleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, et al.JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.Nature Communications|September 1, 2025
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanomaJiekun Yang, Cassia Wang, Doris Fu, et al.Cancer Discovery|September 26, 2024
DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional ReprogrammingIlaria Gritti, Jinkai Wan, Vajira Weeresekara, et al.The Journal of Clinical Psychiatry|February 16, 2017
Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) StudyMadhukar H Trivedi, Tracy L Greer, Chad D Rethorst, et al.Scientific Reports|July 30, 2024
JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humansAnne M Fourie, Xiaoli Cheng, Leon Chang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.Cancer Research|June 8, 2021
Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell SurvivalRiaz Gillani, Bo Kyung A Seong, Jett Crowdis, et al.Pageof 39